Objective To investigate the eff ect of botulinum toxin type A (BTXA) on drooling and the morphologic change of the salivary gland in patients with cerebral palsy. Method Eight cerebral palsy patients suff ering from severe drooling participated in this study. BTXA was injected into both submandibular and parotid glands under intravenous sedation and with ultrasound guidance (1 unit/ gland/kg: maximum 100 units) in an outpatient or inpatient procedure. Th e severity of drooling was measured before injection and 3 weeks after injection using the Teacher Drooling Scale, the Drooling Score-severity, frequency and the Visual Analog Scale. To investigate the morphologic change of the salivary glands, the size of salivary glands were measured before injection and 3 weeks after injection using computed tomography of the neck. Th e measurement values were analyzed by Wilcoxon signed rank test. Results Statistically significant improvements were shown in all three parameters for assessing the severity of drooling after BTXA injections (p<0.05). Size of the salivary glands were signifi cantly decreased at 3 weeks after BTXA injection (p<0.05). Conclusion Salivary gland injection with BTXA could be a useful treatment method to reduce drooling in patients with cerebral palsy and decreased size of salivary glands may partially explain the mechanism.
INTRODUCTION
Drooling is the unintentional loss of saliva from the mouth due to immature or damaged oral motor skills. It occurs more frequently and severely in patients with neurological defi cits such as cerebral palsy, motor neuron disease or Parkinson's disease.
1,2 Persistent drooling may cause adverse events such as problems in social development and dignity of patients, as well as hygiene problems including unpleasant odor, contaminated clothing and furniture, and skin damage by repeated stimulation. 3, 4 Additionally, in patients with brain injury
www.e-arm.org who have swallowing disorders, posterior drooling may cause coughing, nausea, vomiting, aspiration into the airway, and if severe, aspiration pneumonia. 5 Many studies have investigated the clinical improvement in drooling after the injection of botulinum toxin type A (BTXA). In one study, BTXA was injected into rat salivary glands and the resulting change in structure and function was monitored. 6 Another study reported salivary gland shrinkage following the injection of BTXA into rat salivary glands. 7 However, there has been no research studying human subjects. Th is study used neck computed tomography (CT) to compare the size of the salivary glands before and after BTXA injection, aiming to examine morphological changes in the salivary glands along with clinical improvement in drooling after BTXA injection.
MATERIALS AND METHODS

Subjects
From November 2009 to August 2010, eight cerebral palsy patients (6-30 years-of-age; mean 17.25±8.26 years; five men, three women) presented to our hospital for treatment of drooling. Six patients had spastic tetraplegia and two patients had spastic hemiplegia. According to the Gross Motor Function Classifi cation System (GMFCS), one was rated as level 1 and the remaining seven as level 5. Th ey maintained oral feeding (Table 1) .
Methods
To evaluate the effect of BTXA injection on drooling, measurements were done before injection and after 3 weeks using the Teacher Drooling Scale (TDS; Table 2), 1 Drooling Score System (DSS)-severity, frequency (Table  3) , 8 and a 0-10 Visual Analogue Scale (VAS; mild -0 point; severe -10 points). To observe morphological changes in the salivary glands, neck CT was done originating from Frankfort horizontal plane as a basis, which is known to represent the size of salivary glands most accurately, to measure the maximum cross-sectional area (MCSA) in the parotid gland and the submandibular gland before injection and after 3 weeks (Fig. 1) . At this time, individual glands were measured three times to calculate the mean for indicating the size of the salivary glands. BTXA Botox ® (Allergan, CA, USA) was injected into the both submandibular and parotid glands in each patient by ultrasound guidance (1 unit/gland/kg: maximum 100 units). Th e procedure was cooperative in three patients, who underwent aseptic procedures without anesthesia. The remaining patients received an aseptic injection under intravenous sedation using midazolam and fentanyl citrate. Electrical nerve stimulation was used for injection into the parotid glands to confirm that it was not a facial nerve. SPSS 12.0 version for Windows (SPSS, Chicago, USA) was used for statistical analysis; VAS, TDS, 
RESULTS
Changes in VAS, TDS, DSS-severity and frequency
Statistically signifi cant improvements in drooling were shown in all four parameters; from VAS 7.00 (6-8) to 4.00 (2-7), TDS 4.50 (3-5) to 3.00 (2-3), DSS-severity 4.00 (3-5) to 3.00 (2-3), and frequency 4.00 (2-4) to 2.00 (1-3) (p<0.05) ( Table 4) .
Change in size of salivary glands
Th e mean MCSA was statistically signifi cantly reduced after 3 weeks from 3. www.e-arm.org be surgically treated by the changing direction of the secretory duct of parotid glands and removing the salivary glands. However, this might bring about complications such as dysphagia, airway stenosis, and xerostomia. 14, 15 Since the 1997 report that drooling is improved by BTXA injection into the salivary glands in patients with amyotrophic lateral sclerosis, 16 injection of BTXA into the salivary glands in patients with brain injury including cerebral palsy has been attempted. Th e collective results have led to the view that BTXA injection is an eff ective treatment for improving drooling without signifi cant adverse events compared to existing methods such as the use of anti-cholinergic agents or surgery. [17] [18] [19] Salivary secretion is regulated by the autonomic nervous system; the sympathetic system primarily controls composition of saliva while the parasympathetic system regulates the secretion amount. As acetylcholine is secreted at the terminals of parasympathetic nerve fi bers, saliva is produced. 20 When BTXA reaches the target tissue, it is internalized via endocytosis into the nerve cells at the axon terminal, where it binds to the soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) protein complex, which contributes to release of acetylcholine, resulting in proteolytic cleavage of the SNARE protein complex. It is assumed, but as yet unproven, that BTXA reduces drooling by suppressing the secretion of acetylcholine in the neuroglandular junction, the terminal of parasympathetic nerve fi bers.
21,22
Coskun et al. 7 injected BTXA into the submandibular glands of 15 rats, 4 to 6-month-old rats and observed morpho logical changes using ultrasound. Shrinkage of salivary glands were observed at 2 and 4 weeks after injection. However, there was no particular change other than lymphocyte infiltration in histologic examination. On the other hand, Teymoortash et al. 6 injected BTXA and saline into rat submandibular glands and examined morphological change through histologic examination, and observed shrinkage of glandular cells, decreased size of acinar cells, and reduced granules in acinar cells. It is assumed that the action of SNARE protein complex is controlled by BTXA, causing denervation due to suppressed release of acetylcholine in the neuroglandular junction, resulting in decreased secretion of granules from acinar cells. To date, studies have attempted to clarify the action mechanism of BTXA, which reduces drooling, in the salivary glands of animals. However, little is known concerning human subjects. This study used CT to identify clinical improvement in drooling and morphological changes in the salivary glands after BTXA injection. According to Heo et al., 9 neck CT originating from Frankfort horizontal plane as a basis most accurately represent the size of salivary glands. Thus, CT was used to measure and compare the mean size of salivary glands before injection and after 3 weeks based on the method above, confirming the clinical improvement in drooling and signifi cant reduction of salivary gland size after 3 weeks of injection. Our results with cerebral palsy patients echo those of Coskun et al. 7 , who suggested that BTXA injection in patients with cerebral palsy leads to shrinkage of salivary glands and it might contribute to clinical improvement in drooping. Th e present result may corroborate the suggestion of Jongerius et al. 1 that the BTXA eff ect lasts longer by repeated injection in patients with cerebral palsy because of salivary glands shrunk due to denervation. However, in this study, there were few subjects and no histologic examination was performed so that it could not observe any histologic change in salivary gland cells after injection. It might be helpful to demonstrate the action mechanism of BTXA in the salivary glands by longterm follow-up for BTXA injection and changes in the size of salivary glands with more patients, or additional research on correlation between the degree of shrinkage of salivary glands and the degree of improvement in drooling.
CONCLUSION
BTXA was injected into the salivary glands in patients with cerebral palsy having severe drooling, demonstrating clinical improvement in drooling. CT performed before injection and after 3 weeks was done to show the action mechanism of BTXA in the salivary glands, resulting in significant reduction in its size. Therefore, it is thought that shrinkage of salivary glands might contribute to improvement of drooling.
